Resultado de búsqueda
1 de may. de 2014 · AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC. Patients and methods: Eligible patients had measurable/assessable OC that had progressed < 6 months after completing platinum-based therapy.
17 de mar. de 2014 · The AURELIA trial met its primary objective, demonstrating statistically significant improvement in PFS (HR, 0.48; 95% CI, 0.38 to 0.60) with the addition of bevacizumab to chemotherapy for platinum-resistant ovarian cancer.
20 de jun. de 2012 · AURELIA is the first randomized trial of BEV in PT-resistant OC. Methods: Eligible patients (pts) had OC (measurable by RECIST 1.0 or assessable) that had progressed ≤6 mo after ≥4 cycles of PT-based therapy.
29 de dic. de 2011 · Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for ...
22 de nov. de 2019 · The AURELIA (Avastin Use in Platinum-Resistant Epithelial Ovarian Cancer) trial was the first phase III randomized controlled trial to combine BEV with standard chemotherapy for women with platinum-resistant ovarian cancer.
AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC. (Basel, Switzerland), which also provided third-party writing assistance (Jennifer Kelly, Medi-Kelsey Limited, Ashbourne, United Kingdom).
In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS).
